{"disease":{"id":"her2-amplified-breast-cancer","name":"her2 amplified breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04482309","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":477,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02091960","title":"A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":103,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT04366713","title":"A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Puma Biotechnology, Inc.","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}